These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35373026)

  • 1. A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD.
    Nowak KL; Kakkar R; Devalaraja M; Lo L; Park W; Gobburu J; Kling D; Davidson M; Chonchol M
    Kidney360; 2021 Feb; 2(2):224-235. PubMed ID: 35373026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Ridker PM; Devalaraja M; Baeres FMM; Engelmann MDM; Hovingh GK; Ivkovic M; Lo L; Kling D; Pergola P; Raj D; Libby P; Davidson M;
    Lancet; 2021 May; 397(10289):2060-2069. PubMed ID: 34015342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Pergola PE; Devalaraja M; Fishbane S; Chonchol M; Mathur VS; Smith MT; Lo L; Herzog K; Kakkar R; Davidson MH
    J Am Soc Nephrol; 2021 Jan; 32(1):211-222. PubMed ID: 33272965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
    Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
    J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD.
    Gregg LP; Carmody T; Le D; Bharadwaj N; Trivedi MH; Hedayati SS
    Kidney360; 2020 Jun; 1(6):436-446. PubMed ID: 35368605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus.
    Noe A; Howard C; Thuren T; Taylor A; Skerjanec A
    Clin Ther; 2014 Nov; 36(11):1625-37. PubMed ID: 25240532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients.
    Fu EL; Franko MA; Obergfell A; Dekker FW; Gabrielsen A; Jernberg T; Carrero JJ
    Am Heart J; 2019 Oct; 216():20-29. PubMed ID: 31382219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of OMEGA-3 Fatty Acid Supplementation Upon Interleukin-12 and Interleukin-18 in Chronic Kidney Disease Patients.
    Yong K; Mori T; Chew G; Beilin LJ; Puddey I; Watts GF; Irish A; Dogra G; Boudville N; Lim W
    J Ren Nutr; 2019 Sep; 29(5):377-385. PubMed ID: 30803749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-1 Inhibition and Vascular Function in CKD.
    Nowak KL; Chonchol M; Ikizler TA; Farmer-Bailey H; Salas N; Chaudhry R; Wang W; Smits G; Tengesdal I; Dinarello CA; Hung AM
    J Am Soc Nephrol; 2017 Mar; 28(3):971-980. PubMed ID: 27647856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy.
    Ridker PM; Tuttle KR; Perkovic V; Libby P; MacFadyen JG
    Eur Heart J; 2022 Dec; 43(46):4832-4844. PubMed ID: 35943897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.
    Ridker PM; MacFadyen J; Cressman M; Glynn RJ
    J Am Coll Cardiol; 2010 Mar; 55(12):1266-1273. PubMed ID: 20206456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome.
    Batra G; Ghukasyan Lakic T; Lindbäck J; Held C; White HD; Stewart RAH; Koenig W; Cannon CP; Budaj A; Hagström E; Siegbahn A; Wallentin L;
    JAMA Cardiol; 2021 Dec; 6(12):1440-1445. PubMed ID: 34431970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical Trial.
    Adamstein NH; Cornel JH; Davidson M; Libby P; de Remigis A; Jensen C; Ekström K; Ridker PM
    JAMA Cardiol; 2023 Feb; 8(2):177-181. PubMed ID: 36449307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Not all inflammatory markers are linked to kidney function: results from a population-based study.
    Pruijm M; Ponte B; Vollenweider P; Mooser V; Paccaud F; Waeber G; Marques-Vidal P; Burnier M; Bochud M
    Am J Nephrol; 2012; 35(3):288-94. PubMed ID: 22398717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial.
    Ridker PM; MacFadyen JG; Glynn RJ; Bradwin G; Hasan AA; Rifai N
    Eur Heart J; 2020 Aug; 41(31):2952-2961. PubMed ID: 32221587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ;
    Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between pulse pressure and inflammation with left ventricular diastolic dysfunction in chronic kidney disease patients.
    Yong K; Mori T; Chew G; Beilin LJ; Puddey I; Watts G; Dogra G; Boudville N; Lim W
    Intern Med J; 2019 Feb; 49(2):240-247. PubMed ID: 29992694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD.
    Sun J; Axelsson J; Machowska A; Heimbürger O; Bárány P; Lindholm B; Lindström K; Stenvinkel P; Qureshi AR
    Clin J Am Soc Nephrol; 2016 Jul; 11(7):1163-1172. PubMed ID: 27281698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
    Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
    Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage, is associated with mortality independent of inflammation in chronic kidney disease.
    Dai L; Watanabe M; Qureshi AR; Mukai H; Machowska A; Heimbürger O; Barany P; Lindholm B; Stenvinkel P
    Eur J Intern Med; 2019 Oct; 68():60-65. PubMed ID: 31402276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.